CD30 in Systemic Mastocytosis
- 1 May 2014
- journal article
- review article
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 34 (2) , 341-355
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- CD30 Ligand/CD30 Interaction Is Involved in Pathogenesis of Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2012
- High Soluble CD30, CD25, and IL-6 May Identify Patients with Worse Survival in CD30+ Cutaneous Lymphomas and Early Mycosis FungoidesJournal of Investigative Dermatology, 2012
- A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cellsBiological Chemistry, 2012
- EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*Blood, 2011
- The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in miceEuropean Journal of Immunology, 2011
- CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma CellsThe American Journal of Pathology, 2008
- Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretionJournal of Clinical Investigation, 2006
- Deciphering CD30 ligand biology and its role in humoral immunityImmunology, 2006
- RETRACTED: Silencing of B Cell Receptor Signals in Human Naive B CellsJournal of Experimental Medicine, 2002
- The role of Epstein—Barr virus in the pathogenesis of Hodgkin's diseaseAnnals of Oncology, 1996